TP53 is an inclusion criterion in 19 clinical trials for chronic lymphocytic leukemia, of which 13 are open and 6 are closed. Of the trials that contain TP53 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), 9 are phase 2 (9 open), and 1 is phase 3 (0 open) [4].

Idelalisib and rituximab have evidence of efficacy in patients with TP53 mutation in chronic lymphocytic leukemia [4].

TP53 is an inclusion criterion in 113 clinical trials for acute myeloid leukemia, of which 71 are open and 42 are closed. Of the trials that contain TP53 status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 35 are phase 1 (19 open), 19 are phase 1/phase 2 (13 open), 46 are phase 2 (31 open), 2 are phase 2/phase 3 (1 open), 8 are phase 3 (6 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 74 clinical trials for myelodysplastic syndromes, of which 48 are open and 26 are closed. Of the trials that contain TP53 status and myelodysplastic syndromes as inclusion criteria, 2 are early phase 1 (1 open), 26 are phase 1 (14 open), 13 are phase 1/phase 2 (11 open), 28 are phase 2 (19 open), 1 is phase 2/phase 3 (0 open), 3 are phase 3 (3 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 41 clinical trials for acute lymphoblastic leukemia, of which 24 are open and 17 are closed. Of the trials that contain TP53 status and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 16 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), 18 are phase 2 (11 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 27 clinical trials for chronic myeloid leukemia, of which 16 are open and 11 are closed. Of the trials that contain TP53 status and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 11 are phase 1 (7 open), 4 are phase 1/phase 2 (4 open), 10 are phase 2 (5 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 21 clinical trials for hodgkin lymphoma, of which 12 are open and 9 are closed. Of the trials that contain TP53 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 21 clinical trials for multiple myeloma, of which 15 are open and 6 are closed. Of the trials that contain TP53 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 9 are phase 1 (6 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (6 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 19 clinical trials for chronic myelomonocytic leukemia, of which 15 are open and 4 are closed. Of the trials that contain TP53 status and chronic myelomonocytic leukemia as inclusion criteria, 6 are phase 1 (3 open), 6 are phase 1/phase 2 (6 open), and 7 are phase 2 (6 open) [4].

TP53 is an inclusion criterion in 18 clinical trials for non-hodgkin lymphoma, of which 10 are open and 8 are closed. Of the trials that contain TP53 status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 7 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), and 7 are phase 2 (5 open) [4].

TP53 is an inclusion criterion in 15 clinical trials for malignant solid tumor, of which 9 are open and 6 are closed. Of the trials that contain TP53 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (4 open), 5 are phase 1/phase 2 (3 open), and 3 are phase 2 (2 open) [4].

TP53 is an inclusion criterion in 14 clinical trials for acute biphenotypic leukemia, of which 7 are open and 7 are closed. Of the trials that contain TP53 status and acute biphenotypic leukemia as inclusion criteria, 7 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (2 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 12 clinical trials for mantle cell lymphoma, of which 7 are open and 5 are closed. Of the trials that contain TP53 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (2 open), 5 are phase 2 (3 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 11 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 6 are open and 5 are closed. Of the trials that contain TP53 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 8 are phase 2 (5 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 10 clinical trials for medulloblastoma, of which 10 are open and 0 are closed. Of the trials that contain TP53 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [4].

TP53 is an inclusion criterion in 10 clinical trials for non-small cell lung carcinoma, of which 5 are open and 5 are closed. Of the trials that contain TP53 status and non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 4 are phase 2 (2 open) [4].

TP53 is an inclusion criterion in 9 clinical trials for lymphoma, of which 5 are open and 4 are closed. Of the trials that contain TP53 status and lymphoma as inclusion criteria, 6 are phase 1 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

TP53 is an inclusion criterion in 8 clinical trials for Burkitt lymphoma, of which 3 are open and 5 are closed. Of the trials that contain TP53 status and Burkitt lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 7 clinical trials for acute leukemia, of which 2 are open and 5 are closed. Of the trials that contain TP53 status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 7 clinical trials for anaplastic large cell lymphoma, of which 3 are open and 4 are closed. Of the trials that contain TP53 status and anaplastic large cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 7 clinical trials for follicular lymphoma, of which 3 are open and 4 are closed. Of the trials that contain TP53 status and follicular lymphoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain TP53 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [4].

TP53 is an inclusion criterion in 7 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 6 are open and 1 is closed. Of the trials that contain TP53 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (2 open) [4].

TP53 is an inclusion criterion in 7 clinical trials for myeloproliferative neoplasm, of which 4 are open and 3 are closed. Of the trials that contain TP53 status and myeloproliferative neoplasm as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 7 clinical trials for ovarian carcinoma, of which 2 are open and 5 are closed. Of the trials that contain TP53 status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [4].

TP53 is an inclusion criterion in 6 clinical trials for breast carcinoma, of which 2 are open and 4 are closed. Of the trials that contain TP53 status and breast carcinoma as inclusion criteria, 4 are phase 1 (2 open) and 2 are phase 2 (0 open) [4].

TP53 is an inclusion criterion in 6 clinical trials for marginal zone lymphoma, of which 2 are open and 4 are closed. Of the trials that contain TP53 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 6 clinical trials for myelofibrosis, of which 2 are open and 4 are closed. Of the trials that contain TP53 status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), and 2 are phase 2 (1 open) [4].

TP53 is an inclusion criterion in 6 clinical trials for small lymphocytic lymphoma, of which 3 are open and 3 are closed. Of the trials that contain TP53 status and small lymphocytic lymphoma as inclusion criteria, 4 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 2 are closed. Of the trials that contain TP53 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (1 open) [4].

TP53 is an inclusion criterion in 5 clinical trials for colorectal carcinoma, of which 2 are open and 3 are closed. Of the trials that contain TP53 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 5 clinical trials for diffuse large B-cell lymphoma, of which 4 are open and 1 is closed. Of the trials that contain TP53 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), and 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 5 clinical trials for prolymphocytic leukemia, of which 3 are open and 2 are closed. Of the trials that contain TP53 status and prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 5 clinical trials for prostate carcinoma, of which 3 are open and 2 are closed. Of the trials that contain TP53 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [4].

TP53 is an inclusion criterion in 5 clinical trials for refractory anemia with excess blasts, of which 3 are open and 2 are closed. Of the trials that contain TP53 status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [4].

TP53 is an inclusion criterion in 5 clinical trials for secondary acute myeloid leukemia, of which 5 are open and 0 are closed. Of the trials that contain TP53 status and secondary acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (2 open) [4].

TP53 is an inclusion criterion in 4 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain TP53 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [4].

TP53 is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain TP53 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [4].

TP53 is an inclusion criterion in 4 clinical trials for glioblastoma, of which 1 is open and 3 are closed. Of the trials that contain TP53 status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain TP53 status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].

TP53 is an inclusion criterion in 4 clinical trials for mixed phenotype acute leukemia, of which 3 are open and 1 is closed. Of the trials that contain TP53 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (2 open) [4].

TP53 is an inclusion criterion in 4 clinical trials for plasma cell leukemia, of which 2 are open and 2 are closed. Of the trials that contain TP53 status and plasma cell leukemia as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (2 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for anaplastic astrocytoma, of which 1 is open and 2 are closed. Of the trials that contain TP53 status and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 1 is open and 2 are closed. Of the trials that contain TP53 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for endometrial serous adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain TP53 status and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for fallopian tube carcinoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 status and fallopian tube carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for gastric adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 2 are closed. Of the trials that contain TP53 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for lymphoblastic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 0 are open and 3 are closed. Of the trials that contain TP53 status and lymphoplasmacytic lymphoma as inclusion criteria, 2 are phase 2 (0 open) and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for medulloblastoma, WNT-activated, of which 3 are open and 0 are closed. Of the trials that contain TP53 status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 2 are closed. Of the trials that contain TP53 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 3 are phase 2 (1 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for primary peritoneal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for small cell lung carcinoma, of which 1 is open and 2 are closed. Of the trials that contain TP53 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain TP53 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain TP53 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain TP53 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

TP53 is an inclusion criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain TP53 status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for acute undifferentiated leukemia, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for colorectal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain TP53 status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for esophageal squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain TP53 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for leukemia, of which 1 is open and 1 is closed. Of the trials that contain TP53 status and leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain TP53 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain TP53 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for myeloid neoplasm, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 1 is closed. Of the trials that contain TP53 status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 2 are phase 2 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain TP53 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for primary peritoneal serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for refractory anemia, of which 1 is open and 1 is closed. Of the trials that contain TP53 status and refractory anemia as inclusion criteria, 2 are phase 2 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain TP53 status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

TP53 is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for acute bilineal leukemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and acute bilineal leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for acute erythroid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and acute erythroid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for acute megakaryoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2/phase 3 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for acute promyelocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and acute promyelocytic leukemia as inclusion criteria, 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for adult acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and adult acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for anaplastic oligoastrocytoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and anaplastic oligoastrocytoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for B-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for breast lobular carcinoma in situ, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and breast lobular carcinoma in situ as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-0, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and chronic myelomonocytic leukemia-0 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-1, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and chronic myelomonocytic leukemia-1 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and endometrial carcinoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for fallopian tube endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for gastric squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and gastric squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for gliosarcoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and gliosarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for hereditary breast and ovarian cancer syndrome, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and hereditary breast and ovarian cancer syndrome as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for kidney carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and kidney carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and malignant gastric neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for malignant testicular neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and malignant testicular neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for ovarian serous tumor, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and ovarian serous tumor as inclusion criteria, 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for primary peritoneal endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and primary peritoneal endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for smoldering plasma cell myeloma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and smoldering plasma cell myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for uterine carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and uterine carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for WHO grade III glioma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and WHO grade III glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

TP53 is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (1 open) [4].